Join our growing team! Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
View Top Employees from Alkeus Pharmaceuticals, Inc.Website | http://www.alkeus.com |
Revenue | $2.4 million |
Employees | 35 (14 on RocketReach) |
Founded | 2010 |
Address | 278 Elm St, Ste 229, Somerville, Massachusetts 02144, US |
Phone | (800) 287-2755 |
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Science and Engineering, Healthcare, Medical, Health Care, Medical Device, Pharmaceutical |
Web Rank | 7 Million |
Keywords | Vision Of Stargardt, Alkeus Pharmaceuticals, Alkeus Pharmaceuticals Clinical Research Coordinator, Leonide Saad, Alkeu Pharmaceuticals |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Alkeus Pharmaceuticals, Inc. employee's phone or email?
The Alkeus Pharmaceuticals, Inc. annual revenue was $2.4 million in 2024.
14 people are employed at Alkeus Pharmaceuticals, Inc..
Alkeus Pharmaceuticals, Inc. is based in Somerville, Massachusetts.
The NAICS codes for Alkeus Pharmaceuticals, Inc. are [3254, 32541, 32, 325].
The SIC codes for Alkeus Pharmaceuticals, Inc. are [283, 28].